摘要
目的利用转基因HepG2,215细胞进行体外联合抗乙型肝炎病毒(HBV)的实验研究,为临床治疗提供参考。方法在细胞生长液中加入适当浓度配制的拉米夫定、α_2a干扰素(罗荛愫)、胸腺肽α1(日达仙)以及拉米夫定分别与α_2a干扰素、胸腺肽α1的配伍制剂。常规培养并采用ELISA法检测该细胞分泌的HBsAg和HBeAg,以计算抑制率的方法判定药物抗HBV的作用。结果拉米夫定具有体外直接抗病毒作用。三者联合应用具有协同抗病毒作用。结论核苷类药物具有直接抗病毒作用,而且与免疫调节剂联合应用可以增强抗HBV作用,达到优势互补的效果。
Objective Using transgenic HepG2,215 cell to study the combining anti-HBV effect of lamivudine,interferon α-2a and thymosin-α1. Methods Lamivudine,interferon α-2a,thymosin-α1 and combination of lamivudine with interferon (α-2a) and with thymosin-α1 were added into the cell culture liquid respectively.After routine culture,HBsAg and HBeAg (excreted) by the cells were detected using ELISA.Inhibition rates were calculated to evaluate the antiviral effect. (Results) Lamivudine has antiviral effects.Combination of lamivudine with interferon α-2a and with thymosin-α1 shows synergistic antiviral effects. Conclusions Lamivudine can play a direct anti-HBV role. The combination of lamivudine and immune modulator can enhance antiviral effects.
